EEC revealed violations of competition in the common drug market of the EAEU

The Eurasian Economic Commission conducted a study of the pharmaceutical industry of the Eurasian Economic Union and revealed violations of competition. This was reported to sb.by by the press service of the Eurasian Economic Commission with reference to a member of the Board (Minister) for Competition and Antimonopoly Regulation of the EEC Maxim Yermolovich.

The study revealed differences in the law enforcement of the Union’s general norms at the national level, uneven registration of medicines under uniform rules, a high threshold for entry into the market, features of determining the interchangeability of drugs for public procurement purposes, and other market conditions that distort competition. Minister of the Eurasian Economic Commission Maxim Yermolovich noted that the Commission sent information to the EAEU states about the results of the study in order to implement the tasks in the field of competition defined by the Treaty on the EAEU. EEC defines approaches to development of high-speed railways in EAEU